Islamabad, 10 June: French Prime Minister Jean Castex is placing himself under seven days quarantine after his wife tested positive for COVID-19, his office announced.
Castex has received a first AstraZeneca vaccination against Covid-19 and had a negative test in the evening, the prime minister´s office said.
“Nevertheless, as a contact case, he is in solitary confinement for seven days, in accordance with health rules,” it added.
Earlier Wednesday Castex met members of the public while carrying out his prime ministerial duties on a day that France further relaxed its Covid-19 restrictions, with people enjoying indoor dining and gyms for the first time in months.
French Prime Minister visited a market and a sports hall in a Paris suburb before having lunch with Economy Minister Bruno Le Maire.
He also took part in the first almost-complete ministerial meeting since October.
The reopenings come as France — one of Europe´s hardest hit countries — sees a drop off in coronavirus cases after a grim winter.
The numbers in intensive care are down to 2,394 compared with 6,000 in late April.
The government is on course to reach its target of 30 million people with at least one dose of the vaccine by June 15.
Castex goes into isolation for the third time in under a year, after coming into contact with Tour de France race director Christian Prudhomme in September and President Emmanuel Macron in December, both of whom had contracted the virus.
However the prime minister has never tested positive for coronavirus.
He is also due soon to receive his second dose of the vaccine.
Read this: Early warning signs of Ovarian Cancer
Ovarian cancer commonly known as the “silent killer“. It leads to approximately 15,000 deaths each year only in the United States, according to the American Cancer Society.
Approximately 20,000 new cases are diagnosed each year, with the majority in patients diagnosed with late stage disease where the cancer has spread beyond the ovary.
The prognosis is poor in these patients, leading to the high mortality from this disease.
A diagnostic test is needed that can provide adequate predictive value to stratify patients with a pelvic mass into high risk of invasive.